Unlisted
Stock Code: 446600
| Company Name | (주)카이바이오텍 |
| English Name | KaiBioTech Co., Ltd |
| Business Reg. No. | 4188142520 |
| CEO | 김영덕 |
| Address | 전라북도 전주시 덕진구 백제대로567(금암동) |
| Industry | 합성의약품 및 기타 완제 의약품 제조업 |
| Industry Code | 212 |
| Main Products | 방사성 진단,치료 의약품 제조 |
| Established | 20121218 |
| Phone | 063-219-5510 |
| Website | www.kaibiotech.com/ |
| Regular Employees | Contact |
| Corp. Reg. No. | 2101110087512 |
Venture Certified
| 기술평가보증기업(기금) | 2014-04-11 ~ 2016-04-10 | 20140104146 | 2014-04-11 |
| 연구개발유형 | 2016-04-11 ~ 2018-04-10 | 20160104031 | 2014-04-11 |
| 연구개발유형 | 2018-04-11 ~ 2020-04-10 | 20180103743 | 2014-04-11 |
| 벤처투자유형 | 2020-04-11 ~ 2022-04-10 | 20200300360 | 2014-04-11 |
| 벤처투자유형 | 2022-04-11 ~ 2025-04-10 | 20220428010036 | 2014-04-11 |
| 벤처투자유형 | 2025-04-11 ~ 2028-04-10 | 20250430010014 | 2014-04-11 |
Revenue CAGR +7.5%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 52B | 46B | 45B |
| Operating Profit | -3.7B | -2.0B | -5.0B |
| Net Profit | -2.3B | -2.9B | -5.7B |
| Total Assets | 43B | 45B | 46B |
| Total Liabilities | 44B | 44B | 44B |
| Total Equity | -1.4B | 0.9B | 2.6B |
Capital Erosion: Total equity is negative or below 50% of capital stock
Operating Loss: Op. profit -4B
3 Consecutive Years of Net Loss
▲ 14.0%
▼ 4.8%
▲ 8.7%
▼ 197.3%
▲ 161.5%
| Shareholder | Ownership (%) | Shares Held |
|---|---|---|
| - | ||
| - | ||
| - | ||
| - |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "전북 전주시",
"ceo_name": "김영덕",
"certificate": [
{
"cert_number": "20140104146",
"changes": "",
"disclosure_date": "2014-04-11",
"first_cert_date": "2014-04-11",
"no": "1",
"type": "기술평가보증기업(기금)",
"valid_period": "2014-04-11 ~ 2016-04-10"
},
{
"cert_number": "20160104031",
"changes": "",
"disclosure_date": "2016-04-08",
"first_cert_date": "2014-04-11",
"no": "2",
"type": "연구개발유형",
"valid_period": "2016-04-11 ~ 2018-04-10"
},
{
"cert_number": "20180103743",
"changes": "",
"disclosure_date": "2018-04-05",
"first_cert_date": "2014-04-11",
"no": "3",
"type": "연구개발유형",
"valid_period": "2018-04-11 ~ 2020-04-10"
},
{
"cert_number": "20200300360",
"changes": "",
"disclosure_date": "2020-03-26",
"first_cert_date": "2014-04-11",
"no": "4",
"type": "벤처투자유형",
"valid_period": "2020-04-11 ~ 2022-04-10"
},
{
"cert_number": "20220428010036",
"changes": "",
"disclosure_date": "2022-04-28",
"first_cert_date": "2014-04-11",
"no": "5",
"type": "벤처투자유형",
"valid_period": "2022-04-11 ~ 2025-04-10"
},
{
"cert_number": "20250430010014",
"changes": "",
"disclosure_date": "2025-04-30",
"first_cert_date": "2014-04-11",
"no": "6",
"type": "벤처투자유형",
"valid_period": "2025-04-11 ~ 2028-04-10"
}
],
"company_name": "(주)카이바이오텍",
"corp_no": "210111-*******",
"financials": {
"2022": {
"capital_stock": 5360955000,
"cost_of_sales": 3316482000,
"current_assets": 2429122000,
"current_liabilities": 1097058000,
"gross_profit": 1167031000,
"net_income": -571495000,
"net_income_bs": -571495000,
"non_current_assets": 2185142000,
"non_current_liabilities": 3258629000,
"non_operating_expenses": 123288000,
"non_operating_income": 55120000,
"operating_profit": -503327000,
"revenue": 4483512000,
"sga_expenses": 1670357000,
"total_assets": 4614264000,
"total_equity": 258576000,
"total_liabilities": 4355688000
},
"2023": {
"capital_stock": 5360955000,
"cost_of_sales": 4131357000,
"current_assets": 2558733000,
"current_liabilities": 4207129000,
"gross_profit": 480518000,
"net_income": -289051000,
"net_income_bs": -289050000,
"non_current_assets": 1918272000,
"non_current_liabilities": 178193000,
"non_operating_expenses": 127367000,
"non_operating_income": 35141000,
"operating_profit": -196825000,
"revenue": 4611875000,
"sga_expenses": 677343000,
"total_assets": 4477004000,
"total_equity": 91683000,
"total_liabilities": 4385321000
},
"2024": {
"capital_stock": 5360955000,
"cost_of_sales": 4877570000,
"current_assets": 2592312000,
"current_liabilities": 1191269000,
"gross_profit": 308440000,
"net_income": -233095000,
"net_income_bs": -233095000,
"non_current_assets": 1713652000,
"non_current_liabilities": 3256107000,
"non_operating_expenses": 112022000,
"non_operating_income": 245737000,
"operating_profit": -366810000,
"revenue": 5186010000,
"sga_expenses": 675250000,
"total_assets": 4305965000,
"total_equity": -141412000,
"total_liabilities": 4447377000
}
},
"industry": "합성의약품 및 기타 완제 의약품 제조업",
"investment": [
{
"amount": "1,000,000,000",
"changes": "1,000,000,000",
"date": "2019-07-29"
},
{
"amount": "1,000,010,000",
"changes": "1,000,010,000",
"date": "2019-07-29"
},
{
"amount": "1,000,000,000",
"changes": "1,000,000,000",
"date": "2019-06-28"
},
{
"amount": "1,500,000,000",
"changes": "1,500,000,000",
"date": "2016-09-12"
},
{
"amount": "1,500,000,000",
"changes": "1,500,000,000",
"date": "2016-09-12"
}
],
"main_products": "방사성 진단,치료 의약품 제조",
"phone": "063-219-****",
"years": [
2024,
2023,
2022
]
}Data Quality: 8/10 | Primary Source: DART | Section Coverage: 6/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | DART | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Venture System | Collected |
| Officers | DART | Not Collected |
| Employment | Not Collected | Not Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| DART Financial | 2026-02-27 | Collected |
| G2B Procurement | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Venture System Detail | 2026-02-25 | Collected |